HRP20192044T1 - Agonisti i pripravci 5-ht2c receptora i metode uporabe - Google Patents
Agonisti i pripravci 5-ht2c receptora i metode uporabe Download PDFInfo
- Publication number
- HRP20192044T1 HRP20192044T1 HRP20192044TT HRP20192044T HRP20192044T1 HR P20192044 T1 HRP20192044 T1 HR P20192044T1 HR P20192044T T HRP20192044T T HR P20192044TT HR P20192044 T HRP20192044 T HR P20192044T HR P20192044 T1 HRP20192044 T1 HR P20192044T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- individual
- preparation
- diazepino
- difluoroethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 3
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 39
- 230000037396 body weight Effects 0.000 claims 5
- 230000000391 smoking effect Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010057852 Nicotine dependence Diseases 0.000 claims 3
- 208000025569 Tobacco Use disease Diseases 0.000 claims 3
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- KGOOOHQKLRUVSF-VIFPVBQESA-N (3R)-N-(2,2-difluoroethyl)-3-methyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@H](CN3C=2C(=CC=1)CNCC3)C)F KGOOOHQKLRUVSF-VIFPVBQESA-N 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 235000019505 tobacco product Nutrition 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- YOKKCQQJNHEAGV-JTQLQIEISA-N (3R)-N-(2,2-difluoroethyl)-3-(2,2,2-trifluoroethyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@H](CN3C=2C(=CC=1)CNCC3)CC(F)(F)F)F YOKKCQQJNHEAGV-JTQLQIEISA-N 0.000 claims 1
- GJNVOHZANYBSHY-JTQLQIEISA-N (3R)-N-(2,2-difluoroethyl)-3-ethyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@H](CN3C=2C(=CC=1)CNCC3)CC)F GJNVOHZANYBSHY-JTQLQIEISA-N 0.000 claims 1
- YOKKCQQJNHEAGV-SNVBAGLBSA-N (3S)-N-(2,2-difluoroethyl)-3-(2,2,2-trifluoroethyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@@H](CN3C=2C(=CC=1)CNCC3)CC(F)(F)F)F YOKKCQQJNHEAGV-SNVBAGLBSA-N 0.000 claims 1
- GJNVOHZANYBSHY-SNVBAGLBSA-N (3S)-N-(2,2-difluoroethyl)-3-ethyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@@H](CN3C=2C(=CC=1)CNCC3)CC)F GJNVOHZANYBSHY-SNVBAGLBSA-N 0.000 claims 1
- KGOOOHQKLRUVSF-SECBINFHSA-N (3S)-N-(2,2-difluoroethyl)-3-methyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2[C@@H](CN3C=2C(=CC=1)CNCC3)C)F KGOOOHQKLRUVSF-SECBINFHSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000007547 Dravet syndrome Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- NZUCQYVNFSQFJP-UHFFFAOYSA-N N-(2,2-difluoroethyl)-3,3-dimethyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2C(CN3C=2C(=CC=1)CNCC3)(C)C)F NZUCQYVNFSQFJP-UHFFFAOYSA-N 0.000 claims 1
- KGOOOHQKLRUVSF-UHFFFAOYSA-N N-(2,2-difluoroethyl)-3-methyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-5-carboxamide Chemical compound FC(CNC(=O)C=1C=2C(CN3C=2C(=CC=1)CNCC3)C)F KGOOOHQKLRUVSF-UHFFFAOYSA-N 0.000 claims 1
- QPYBSRUZCOSWDJ-UHFFFAOYSA-N N-(2,2-difluoroethyl)spiro[1,10-diazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-3,1'-cyclobutane]-5-carboxamide Chemical compound FC(CNC(=O)C=1C2=C3C(=CC=1)CNCCN3CC21CCC1)F QPYBSRUZCOSWDJ-UHFFFAOYSA-N 0.000 claims 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (24)
1. Spoj odabran između sljedećih spojeva, i njihovih farmaceutski prihvatljivih soli, hidrata i solvata:
N-(2,2-difluoroetil)-7-metil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 1);
(S)-N-(2,2-difluoroetil)-7-metil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 2);
(R)-N-(2,2-difluoroetil)-7-metil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 3);
(S)-N-(2,2-difluoroetil)-7-etil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 4);
(R)-N-(2,2-difluoroetil)-7-etil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 5);
N-(2,2-difluoroetil)-7,7-dimetil-1,2,3,4,6,7-heksahidro-[1,4]diazepino [6,7,1-hi]indol-8-karboksamid (Spoj Br. 6);
N-(2,2-difluoroetil)-2,3,4,6-tetrahidro-1H-spiro[[1,4]diazepino [6,7,1-hi]indol-7,1’-ciklobutan]-8-karboksamid (Spoj Br. 7);
(S)-N-(2,2-difluoroetil)-7-(2,2,2-trifluoroetil)-1,2,3,4,6,7-heksahidro-[1,4]diazepino[6,7,1-hi]indol-8-karboksamid (Spoj Br. 8); i
(R)-N-(2,2-difluoroetil)-7-(2,2,2-trifluoroetil)-1,2,3,4,6,7-heksahidro-[1,4]diazepino[6,7,1-hi]indol-8-karboksamid (Spoj Br. 9).
2. Spoj sukladno zahtjevu 1 pri čemu je spoj (R)-N-(2,2-difluoroetil)-7-metil-1,2,3,4,6,7-heksahidro-[1,4]diazepino[6,7,1-hi]indol-8-karboksamid (Spoj Br. 3) ili farmaceutski prihvatljiva sol, hidrat ili solvat istih.
3. Farmaceutski pripravak koji obuhvaća spoj sukladno zahtjevu 1 ili zahtjevu 2 i i farmaceutski prihvatljiv nosač.
4. Postupak za pripremu farmaceutskog pripravka, naznačen time da sadrži miješanje spoja iz zahtjeva 1 ili zahtjeva 2 i farmaceutski prihvatljivog nosača.
5. Spoj sukladno zahtjevu 1 ili zahtjevu 2 ili pripravak sukladno zahtjevu 3 za uporabu u postupku liječenja ljudskog ili životinjskog tijela terapijom.
6. Spoj sukladno zahtjevu 1 ili zahtjevu 2 ili pripravak sukladno zahtjevu 3 za uporabu u postupku vezanom za:
smanjenje učestalosti pušenja duhana kod pojedinca koji pokušava smanjiti učestalost pušenja duhana;
pomaganje u prestanku ili smanjenju uporabe duhanskih proizvoda kod pojedinca koji pokušava prestati ili smanjiti uporabu duhanskog proizvoda;
pomoć pri prestanku pušenja i sprečavanju povezanog debljanja;
kontroliranje debljanja povezano s prestankom pušenja od strane pojedinca koji pokušava prestati pušiti duhan;
smanjenje debljanja povezano s prestankom pušenja od strane pojedinca koji pokušava prestati pušiti duhan;
liječenje nikotinske ovisnosti, ovisnosti i/ili prestanka uporabe kod pojedinca koji pokušava liječiti ovisnost o nikotinu,
ovisnost i/ili prestanak uporabe; ili
smanjenje vjerojatnosti ponovne uporabe nikotina kod pojedinca koji pokušava prekinuti uzimanje nikotina.
7. Spoj ili pripravak za upotrebu u skladu s patentnim zahtjevom 6, pri čemu metoda uključuje:
odabir pojedinca s početnim BMI ≥ 27 kg/m2; i
propisivanje i/ili davanje pojedincu učinkovite količine spoja ili pripravka u trajanju od barem jedne godine.
8. Spoj ili pripravak za uporabu sukladno zahtjevu 6, pri čemu postupak obuhvaća:
davanje spoja ili pripravka pojedincu;
nadziranje pojedinčeva BMI tijekom primjene; i
prekidanje primjene ako BMI pojedinca postane < 18.5 kg/m2 tijekom primjene.
9. Spoj ili pripravak za uporabu sukladno zahtjevu 6, pri čemu postupak obuhvaća:
davanje spoja ili pripravka pojedincu s inicijalnim BMI ≤ 25 kg/m2;
nadziranje tjelesne težine pojedinca tijekom primjene; i
prekid navedenog davanja ako se tjelesna težina pojedinca smanji za više od oko 1% tijekom primjene.
10. Spoj ili pripravak za uporabu sukladno zahtjevu 6, pri čemu postupak obuhvaća:
nadziranje tjelesne težine pojedinca tijekom primjene; i
prekid navedenog davanja ako se tjelesna težina pojedinca smanji za više od 1 kg tijekom primjene.
11. Spoj ili pripravak za uporabu sukladno zahtjevima 6 do 10, pri čemu se pojedincu također propisuje i/ili daje dodatno sredstvo.
12. Spoj sukladno zahtjevu 1 ili zahtjevu 2 ili pripravak sukladno zahtjevu 3, naznačen time, da se upotrebljava u postupku za smanjenje unosa hrane kod pojedinca.
13. Spoj iz zahtjeva 1 ili zahtjeva 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku indukcije sitosti kod pojedinca.
14. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja pretilosti kod pojedinca.
15. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku prevencije pretilosti kod pojedinca.
16. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku nadzora tjelesne težine kod pojedinca.
17. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja dijabetesa tipa 2 kod pojedinca.
18. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku prevencije dijabetesa tipa 2 kod pojedinca.
19. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja ovisnosti kod pojedinca.
20. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja ovisnosti o alkoholu kod pojedinca.
21. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja poremećaja vezanog uz napadaje kod pojedinca.
22. Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 21, naznačen time što navedeni poremećaj vezan uz napadaje je epilepsija.
23. Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 21, naznačen time što navedeni poremećaj vezan uz napadaje je Dravet sindrom.
24. Spoj prema zahtjevu 1 ili zahtjevu 2 ili pripravak iz zahtjeva 3, naznačen time, da se upotrebljava u postupku liječenja poremećaja urinarne inkontinencije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153082P | 2015-04-27 | 2015-04-27 | |
| EP16721320.6A EP3288946B1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
| PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192044T1 true HRP20192044T1 (hr) | 2020-02-07 |
Family
ID=55949111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192044TT HRP20192044T1 (hr) | 2015-04-27 | 2019-11-12 | Agonisti i pripravci 5-ht2c receptora i metode uporabe |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10392390B2 (hr) |
| EP (1) | EP3288946B1 (hr) |
| JP (1) | JP6675688B2 (hr) |
| KR (1) | KR102275505B1 (hr) |
| CN (1) | CN107873030B (hr) |
| AU (1) | AU2016255009B2 (hr) |
| BR (1) | BR112017023088B1 (hr) |
| CA (1) | CA3002544C (hr) |
| DK (1) | DK3288946T3 (hr) |
| EA (1) | EA034446B1 (hr) |
| ES (1) | ES2757922T3 (hr) |
| HK (1) | HK1244005B (hr) |
| HR (1) | HRP20192044T1 (hr) |
| HU (1) | HUE047169T2 (hr) |
| IL (1) | IL255171A0 (hr) |
| MX (2) | MX2017013902A (hr) |
| PT (1) | PT3288946T (hr) |
| WO (1) | WO2016176177A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| WO2019152475A1 (en) | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN113692277A (zh) * | 2019-02-08 | 2021-11-23 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| WO2023076533A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| WO2023108165A2 (en) * | 2021-12-10 | 2023-06-15 | GATC Health Corp | Methods of treating addiction and neurological disorders |
| US20230293546A1 (en) * | 2022-03-10 | 2023-09-21 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2023225773A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| WO2002036596A2 (en) * | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| EP1330457B1 (en) * | 2000-11-03 | 2004-10-20 | Wyeth | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| EP2332920A3 (en) * | 2003-06-17 | 2011-12-21 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-04-26 WO PCT/US2016/029308 patent/WO2016176177A1/en active Application Filing
- 2016-04-26 DK DK16721320T patent/DK3288946T3/da active
- 2016-04-26 MX MX2017013902A patent/MX2017013902A/es active IP Right Grant
- 2016-04-26 CA CA3002544A patent/CA3002544C/en active Active
- 2016-04-26 EA EA201792356A patent/EA034446B1/ru not_active IP Right Cessation
- 2016-04-26 AU AU2016255009A patent/AU2016255009B2/en active Active
- 2016-04-26 HU HUE16721320A patent/HUE047169T2/hu unknown
- 2016-04-26 EP EP16721320.6A patent/EP3288946B1/en active Active
- 2016-04-26 JP JP2017555768A patent/JP6675688B2/ja active Active
- 2016-04-26 US US15/567,116 patent/US10392390B2/en active Active
- 2016-04-26 ES ES16721320T patent/ES2757922T3/es active Active
- 2016-04-26 CN CN201680037275.XA patent/CN107873030B/zh active Active
- 2016-04-26 BR BR112017023088-7A patent/BR112017023088B1/pt active IP Right Grant
- 2016-04-26 PT PT167213206T patent/PT3288946T/pt unknown
- 2016-04-26 KR KR1020177033892A patent/KR102275505B1/ko active IP Right Grant
-
2017
- 2017-10-22 IL IL255171A patent/IL255171A0/en active IP Right Grant
- 2017-10-27 MX MX2020005898A patent/MX2020005898A/es unknown
-
2018
- 2018-03-13 HK HK18103485.6A patent/HK1244005B/zh unknown
-
2019
- 2019-11-12 HR HRP20192044TT patent/HRP20192044T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017023088A2 (pt) | 2018-07-10 |
| KR20170140317A (ko) | 2017-12-20 |
| BR112017023088B1 (pt) | 2023-10-03 |
| WO2016176177A1 (en) | 2016-11-03 |
| DK3288946T3 (da) | 2019-11-25 |
| CA3002544C (en) | 2024-03-05 |
| EA034446B1 (ru) | 2020-02-10 |
| JP6675688B2 (ja) | 2020-04-01 |
| US20180186797A1 (en) | 2018-07-05 |
| HK1244005B (zh) | 2020-04-17 |
| ES2757922T3 (es) | 2020-04-30 |
| EA201792356A1 (ru) | 2018-05-31 |
| MX2020005898A (es) | 2020-08-13 |
| IL255171A0 (en) | 2017-12-31 |
| PT3288946T (pt) | 2019-11-27 |
| NZ737412A (en) | 2021-06-25 |
| JP2018519251A (ja) | 2018-07-19 |
| CN107873030A (zh) | 2018-04-03 |
| HUE047169T2 (hu) | 2020-04-28 |
| AU2016255009B2 (en) | 2020-10-08 |
| KR102275505B1 (ko) | 2021-07-08 |
| CN107873030B (zh) | 2021-03-19 |
| EP3288946B1 (en) | 2019-08-21 |
| AU2016255009A1 (en) | 2017-12-14 |
| MX2017013902A (es) | 2018-03-16 |
| EP3288946A1 (en) | 2018-03-07 |
| CA3002544A1 (en) | 2016-11-03 |
| US10392390B2 (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192044T1 (hr) | Agonisti i pripravci 5-ht2c receptora i metode uporabe | |
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| JP2019031502A5 (hr) | ||
| JP2013525291A (ja) | 肝がんの治療に使用するための有機化合物 | |
| Berde et al. | Anesthesia and analgesia during and after surgery in neonates | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| AU2006207498B2 (en) | Use of oxycodone for treating visceral pain | |
| ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
| JP2010535801A5 (hr) | ||
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| HRP20231302T1 (hr) | Način davanja hipnotika/sedativa | |
| NZ583192A (en) | Methods for treating dependence | |
| Kasap et al. | Opioid system mediated anti-nociceptive effect of agomelatine in mice | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| Vera-Portocarrero et al. | Descending facilitatory pathways from the rostroventromedial medulla mediate naloxone-precipitated withdrawal in morphine-dependent rats | |
| JP2012087101A (ja) | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 | |
| LaBonte et al. | The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38 | |
| Capuano et al. | Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol | |
| JP2021138703A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| Levin et al. | Ketanserin attenuates nicotine-induced working memory improvement in rats | |
| US20230293443A1 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| Damasceno et al. | Systemic amitriptyline administration does not prevent the increased thermal response induced by paradoxical sleep deprivation | |
| JP2021530557A (ja) | トラジピタントを用いる処置方法 | |
| JP2015512447A5 (hr) | ||
| Torad et al. | Epidural lidocaine, nalbuphine, and lidocaine–nalbuphine combination in donkeys |